NFKB1 and chronic hepatitis: For instance, the (2S,3R)-5-acetyl-7,3α-dihydroxy-2β-(1-isopropenyl)-2,3-dihydrobenzofuran (1) compound (Figure 1A) has shown potential to inhibit the activation of NF-kB, IL-6, and TNF-α secretion as well as suppression of NF-kB factor expression that have been linked to disorders such as rheumatoid arthritis, chronic hepatitis, and pulmonary fibrosis [56,57].